About 150,998 results

Determining the Long-term Safety and Efficacy of JAK Inhibitors in the Treatment of Dermatomyositis: A Retrospective Cohort Study
Shivani Rangaswamy, Lisa Christopher-Stine, Jemima Albayda et. al.

Nov 14th, 2022 - Background/Purpose: JAK inhibitors have been reported to be a promising treatment for dermatomyositis, an idiopathic inflammatory myopathy. However, the FDA recently added a black box label warning for all JAK inhibitors due to reports indicating increased risk of cardiovascular events, strokes, and cancer. Given these new safety concerns, this study leverages a large North American myositis re...

Efficacy of JAK Inhibitors in Idiopathic Inflammatory Myopathies (other Than Dermatomyositis)
Ana Campar, Ana Sá, Bárbara Oliveira2 and António Marinho et. al.

Nov 14th, 2022 - Background/Purpose: Idiopathic inflammatory myopathies (IIM) are a rare and heterogeneous group of systemic autoimmune disorders, comprising dermatomyositis (DM), immune-mediated necrotizing myopathy (IMNM), polymyositis (PM), inclusion body myositis (IBM) and overlap myositis in which antisynthetase syndrome (ASS) is included. Treatment remains empiric as no on-label drug has been approved so ...

Lenabasum, a Cannabinoid Type 2 Receptor Agonist, Activates Diverse Cell-specific Pathways in Whole Blood Leukocytes in Dermatomyositis
Nilesh Kodali, Thomas Vazquez, DeAnna Diaz et. al.

Nov 14th, 2022 - Background/Purpose: Dermatomyositis (DM) is a systemic autoimmune disease that affects the skin and muscle. Lenabasum, a cannabinoid type 2 receptor (CB2R) agonist, has been developed as a potential treatment to reduce inflammation in DM. Additional research has also shown that lenabasum also exerts its anti-inflammatory effects through the binding of peroxisome proliferator-activated receptor ...

Interferon Alpha Promotes Ultraviolet Light-Mediated Keratinocyte Apoptosis in a Caspase-8 Dependent Manner via Upregulation of Interferon Regulatory Factor 1
Shannon Estadt, Mehrnaz Gharaee-Kermani, Bin Xu et. al.

Nov 14th, 2022 - Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by enhanced sensitivity to ultraviolet radiation (UVR). UVR can trigger cutaneous and systemic disease flares, yet mechanisms driving these responses are not yet fully characterized. Type I interferons (IFNs) are overexpressed in non-lesional SLE skin compared to healthy control skin and promote...

Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)
Robert Spiera, Sebastian Unizony, Kenneth J. Warrington et. al.

Nov 14th, 2022 - Background/Purpose: IL-6 is elevated in patients with active PMR and is associated with disease activity, relapse and severity. Clinical trials with IL-6 receptor (IL-6R) inhibitors in PMR showed higher remission rates and reduced glucocorticoid (GC) use vs GC alone (Mori 2016; Akiyama 2020; Lally 2016, Devauchelle Pensec 2015). The SAPHYR study (NCT03600818) assessed the efficacy and safety of...

Phase II Clinical Trial to Assess the Safety and Efficacy of Tocilizumab in Combination with Ipilimumab and Nivolumab for Treatment-naïve Metastatic Melanoma
Noha Abdel-Wahab, Emma J. Montazari, Christine A. Spillson et. al.

Nov 14th, 2022 - Background/Purpose: Immune checkpoint inhibitors (ICIs) led to impressive survival benefits in treatment of cancers. However, immune-related adverse events (irAEs) can cause treatment discontinuation and sometimes fatalities, more often seen with combination ICIs. Through nanostring gene expression profiling of colitis-irAE, normal colon, and tumor biopsies, we found that the interleukin-6 (IL-...

In Vitro Response to Disease Modifying Antirheumatic Drugs Link Molecular Drug Target with Synovial Transcriptional Signature
Mads Brüner, Ulvi Ahmadov, Morten Aagaard Nielsen et. al.

Nov 14th, 2022 - Background/Purpose: Immune-mediated inflammatory arthritis (IMIA) is a group of diseases characterized by chronic synovitis including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and spondyloarthritis (SpA). Some disease modifying antirheumatic drugs (DMARDs) have demonstrated efficacy in several of these diseases (e.g. TNFα inhibitors) while others have not (e.g. IL-17A inhibitors in ...

Different Humoral but Similar Cellular Responses of Patients with Autoimmune Inflammatory Rheumatic Diseases Under Disease-modifying Anti-rheumatic Drugs After COVID-19 Vaccination
Ioana Andreica, Arturo Blazquez-Navarro, Jan Sokolar et. al.

Nov 14th, 2022 - Background/Purpose: The interplay between humoral and cellular response after vaccination against SARS-CoV-2 in patients (pts.) with autoimmune inflammatory rheumatic diseases (AIRD) remains unknown. To investigate the impact of different immunosuppressive therapies on the development of humoral and cellular immune responses to full 2-dose SARS-CoV-2 vaccination in AIRD pts. with stable low dis...

Comparing the Safety and Effectiveness of Methotrexate, TNF and IL6 Inhibitors for the Treatment of Checkpoint Inhibitor Arthritis
Anne Bass, Noha Abdel-Wahab, Pankti Reid et. al.

Nov 14th, 2022 - Background/Purpose: Immune checkpoint inhibitor associated arthritis (ICI-A) affects ∼4% of ICI-treated cancer patients and often persists. Given its long duration, it is important to identify effective treatments that do not interfere with cancer responses. However, there are no studies comparing the safety or effectiveness of disease modifying anti-rheumatic drugs (DMARDs) for this condition....

Development of the Takayasu’s Arteritis Integrated Disease Activity Index
Chiara Marvisi, Ertugrul Cagri Bolek, Mark Ahlman et. al.

Nov 14th, 2022 - Background/Purpose: Disease activity indices that accurately assess inflammation in Takayasu’s arteritis (TAK) are needed. While clinical assessment is often considered the gold standard, determining if a symptom represents active vasculitis or damage can be challenging in TAK. FDG-PET can directly assess vascular inflammation but specificity of imaging findings, especially in absence of corres...

Dysregulated Interferon Gamma Signals Promote Systemic Autoimmunity in STAT1 Gain of Function Syndrome
Andrea Largent, Jane Buckner, David Rawlings1 and Shaun Jackson et. al.

Nov 14th, 2022 - Background/Purpose: Heterozygous gain-of-function mutations in STAT1 promote a complex disorder of immune dysregulation including chronic mucocutaneous candidiasis (CMC) and systemic autoimmunity. However, given widespread expression of STAT1 in immune and non-immune lineages and engagement by multiple cytokine receptors, the immune mechanisms driving breaks in immune tolerance in STAT1 GOF syn...

Guselkumab Efficacy in Psoriatic Arthritis Assessed by Multi-domain Composite Indices: Data from the Phase 3b COSMOS Trial in a TNFi-IR Population
Laure Gossec, Mohamed Sharaf, Elke Theander et. al.

Nov 14th, 2022 - Background/Purpose: The Phase 3b COSMOS study (NCT03796858) demonstrated the efficacy and safety of guselkumab (GUS), an IL-23 p19 subunit inhibitor, in patients (pts) with psoriatic arthritis (PsA) who had inadequate response (IR; insufficient efficacy or intolerance) to 1–2 tumor necrosis factor inhibitors (TNFi).1 The purpose of this analysis is to assess the efficacy of GUS 100 mg Q8W in TN...

Immunological Differences Between PsA Patients Who Are Tumor Necrosis Factor Inhibitor-Naïve and Who Have Inadequate Response to Tumor Necrosis Factor Inhibitors
Stefan Siebert, Laura Coates, Georg Schett et. al.

Nov 14th, 2022 - Background/Purpose: A better understanding of the immunological differences between psoriatic arthritis (PsA) patients (pts) who are tumor necrosis factor inhibitor (TNFi)-naïve and who have inadequate response to TNFi (TNFi-IR) may guide treatment choices. In DISCOVER-1, benefit of the IL-23p19 subunit inhibitor guselkumab (GUS) every-four-weeks (Q4W) and Q8W over placebo (PBO) in improving Ps...

Long-term Persistence of Second-line Biologics in Psoriatic Arthritis Patients with Prior TNF Inhibitor Exposure: A Nationwide Cohort Study from the French Health Insurance Database
Laura Pina Vegas, Emilie sbidian2 and Pascal Claudepierre, Service de Rhumatologie et. al.

Nov 14th, 2022 - Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are most often the first choice biologic treatment for patients with psoriatic arthritis (PsA). When their discontinuation is needed, a switch to another TNFi or to another therapeutic class may be considered. However, data supporting one approach over the other are lacking. Our objective was to assess the long-term persistence of seco...

Bimekizumab Treatment Results in Improvements in Fatigue and Pain in Biologic DMARD-Naïve or TNFi-IR Patients with Active Psoriatic Arthritis: Pooled 16-Week Results from Two Phase 3 Randomized, Pl...
M. Elaine Husni, Philip J Mease, Joseph Merola et. al.

Nov 14th, 2022 - Background/Purpose: Patients with psoriatic arthritis (PsA) have identified fatigue and pain as important features relevant to their burden of disease.1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, has demonstrated improvements in patient-reported symptoms up to 3 years in a phase 2b study.2 This analysis aimed to assess the impact of BKZ...

Bimekizumab Improvements in Efficacy on Disease Activity Assessed via Composite Endpoints in Biologic DMARD-naïve and TNFi-IR Patients with Active PsA: Pooled 16-Week Results from Phase 3 Randomize...
Philip J Mease, Laura Coates, Robert Landewé et. al.

Nov 14th, 2022 - Background/Purpose: Psoriatic arthritis (PsA) is a disease with multiple manifestations; it is important that the efficacy of new interventions is assessed by composite endpoints across the spectrum of the disease.1 Bimekizumab (BKZ), a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A, has shown efficacy, tolerability, and clinical improvement up to 16 weeks (wks)...

Early Clinical Improvement as Predictor of Long-term Health-Related Quality of Life in Psoriatic Arthritis Patients Treated with Guselkumab: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Iain B McInnes, Enrique R Soriano, Lai-shan Tam et. al.

Nov 14th, 2022 - Background/Purpose: Patients (pts) with PsA experience lower quality of life than both the general population and pts with psoriasis alone1,2. Recent PsA treatment recommendations highlight the importance of maximizing long‐term (LT) health‐related quality of life (HRQoL) and social participation as primary goals of therapy3. We aimed to determine whether early clinical improvement with guselku...

Long-term Efficacy of Guselkumab in Fatigue and Identification of Early Treatment Targets: Post Hoc Analysis Through 2 Years of a Phase 3, Randomized, Double-blind, Placebo-controlled Study Conduct...
Dafna Gladman, Michael Starr, Roberto Ranza et. al.

Nov 14th, 2022 - Background/Purpose: The IL-23p19-subunit inhibitor guselkumab (GUS) demonstrated clinically meaningful improvements in fatigue through one year of treatment1 independent of its effects on ACR20 and MDA achievement2. In this post hoc analysis, the Functional Assessment of Chronic Illness Therapy – Fatigue (FACIT-F) scale was used to: (a) evaluate the long-term effect of GUS in maintaining improv...

Early Skin and Early Enthesitis Responses in Psoriatic Arthritis Patients Treated with Guselkumab Associate with Long-term Response: Post Hoc Analysis Through 2 Years of a Phase 3 Study
Laura Coates, Julio Ramírez, Dennis McGonagle et. al.

Nov 14th, 2022 - Background/Purpose: Guselkumab (GUS), an IL-23p19 inhibitor, has demonstrated efficacy in PsA across key Group for Research and Assessment of Psoriasis (PsO) and Psoriatic Arthritis (GRAPPA)-recommended domains1,2. Skin disease and enthesitis have been identified as disease manifestations with earlier response times than others3. In this analysis we: (a) Determined whether early skin and/or ent...

Serious Infections in Offspring Exposed During Late Pregnancy to Tumour Necrosis Factor Inhibitors with High versus Low Placental Transfer Ability
Leah K. Flatman, Yvan St. Pierre, Isabelle Malhamé et. al.

Nov 14th, 2022 - Background/Purpose: During pregnancy, best practice guidelines suggest discontinuing tumour necrosis factor inhibitors (TNFi) with high placental transfer before or during the third trimester if the maternal disease is well controlled. This recommendation stems from concerns that TNFi, which can cross the placenta, could cause immunosuppression in the offspring, particularly in the third trimes...